Liua X, Zhanga W, Li Z, et al. - Through a prospective, blinded, multicentre, intra-individual comparison study of 112 patients, researchers intended to qualitatively and quantitatively contrast gadobutrol with gadopentetate dimeglumine (Gd-DTPA) in abdominal contrast-enhanced MR angiography (CE-MRA) and contrast-enhanced MRI (CE-MRI) during one-stop imaging. Wilcoxon signed-rank tests showed that gadobutrol was significantly better than Gd-DTPA for small vessels. For large vessel quantity analysis, gadobutrol illustrated significantly higher signal-to-noise ratios in comparison with Gd-DTPA. No statistically important improvement in the liver, spleen, and renal tissue during gadobutrol- and Gd-DTPA-enhanced imaging was noted. One patient stated an adverse event. Dizziness and vomiting occurred following an injection of Gd-DTPA. Hence, the present study exhibits gadobutrol-enhanced MRA was preferred to that of Gd-DTPA without statistical importance in visceral organ improvement. It symbolizes gadobutrol may be more fit for abdominal one-stop imaging for CE-MRA and CE-MRI by enhancing the depiction of vessels in MRA images.